Literature DB >> 10801257

Lessons from genetically engineered animal models XI. Novel mouse models to study pathogenic mechanisms of Crohn's disease.

T T Pizarro1, K O Arseneau, F Cominelli.   

Abstract

Crohn's Disease (CD) affects more than 500,000 individuals in the United States and represents the second most common chronic inflammatory disorder after rheumatoid arthritis. Although major advances have been made in defining the basic mechanisms underlying chronic intestinal inflammation, the precise etiopathogenesis of CD remains unknown. We have recently characterized two novel mouse models of enteritis that express a CD-like phenotype, namely the TNF DeltaARE model of tumor necrosis factor (TNF) overexpression and the SAMP1/Yit model of spontaneous ileitis. The unique feature of these models is that they closely resemble CD for location and histopathology. These genetically manipulated new models of intestinal inflammation offer a powerful tool to investigate potential causes of human disease and may allow the development of novel disease-modifying therapeutic modalities for the treatment of CD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10801257     DOI: 10.1152/ajpgi.2000.278.5.G665

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  19 in total

1.  Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease.

Authors:  M M Kosiewicz; C C Nast; A Krishnan; J Rivera-Nieves; C A Moskaluk; S Matsumoto; K Kozaiwa; F Cominelli
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 2.  Future therapies for inflammatory bowel disease.

Authors:  Stephen J Bickston; Lawrence W Comerford; Fabio Cominelli
Journal:  Curr Gastroenterol Rep       Date:  2003-12

3.  In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1.

Authors:  K Matsuzaki; Y Tsuzuki; H Matsunaga; T Inoue; J Miyazaki; R Hokari; Y Okada; A Kawaguchi; S Nagao; K Itoh; S Matsumoto; S Miura
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

Review 4.  Intestinal stem cells.

Authors:  Shahid Umar
Journal:  Curr Gastroenterol Rep       Date:  2010-10

5.  Altered epithelial cell lineage allocation and global expansion of the crypt epithelial stem cell population are associated with ileitis in SAMP1/YitFc mice.

Authors:  Alda Vidrich; Jenny M Buzan; Sean Barnes; Brian K Reuter; Kirstin Skaar; Chibuzo Ilo; Fabio Cominelli; Theresa Pizarro; Steven M Cohn
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

6.  NaOH-induced Crohn's colitis in rats: a novel experimental model.

Authors:  Erdem Koçak; Seyfettin Köklü; Erdem Akbal; Adnan Taş; Gökhan Karaca; Müzeyyen Hesna Astarcı; Berrak Güven; Murat Can
Journal:  Dig Dis Sci       Date:  2011-04-19       Impact factor: 3.199

Review 7.  Advances in research on animal models of rheumatoid arthritis.

Authors:  Yiping Hu; Wenxiang Cheng; Wenhong Cai; Ye Yue; Jinchao Li; Peng Zhang
Journal:  Clin Rheumatol       Date:  2012-08-11       Impact factor: 2.980

8.  Chemokine and cytokine levels in inflammatory bowel disease patients.

Authors:  Udai P Singh; Narendra P Singh; E Angela Murphy; Robert L Price; Raja Fayad; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Cytokine       Date:  2015-10-29       Impact factor: 3.861

9.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases.

Authors:  Daniel N Frank; Allison L St Amand; Robert A Feldman; Edgar C Boedeker; Noam Harpaz; Norman R Pace
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-15       Impact factor: 11.205

10.  Omega-3 polyunsaturated fatty acids ameliorate the severity of ileitis in the senescence accelerated mice (SAM)P1/Yit mice model.

Authors:  H Matsunaga; R Hokari; C Kurihara; Y Okada; K Takebayashi; K Okudaira; C Watanabe; S Komoto; M Nakamura; Y Tsuzuki; A Kawaguchi; S Nagao; S Miura
Journal:  Clin Exp Immunol       Date:  2009-09-30       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.